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Abstract 
Background: Metastatic spread is responsible for the majority of cancer-associated deaths. 
The tumour microenvironment, including hypoxia, is a major driver of metastasis. The aim of 
this study was to investigate the role of the E3 ligase WSB-1 in breast cancer biology in the 
context of the hypoxic tumour microenvironment, particularly regarding metastatic spread.  
Methods: In this study, WSB-1 expression was evaluated in breast cancer cell lines and 
patient samples. In silico analyses were used to determine the impact of WSB-1 expression 
on distant metastasis-free survival (DMFS) in patients, and correlation between WSB1 
expression and hypoxia gene expression signatures. The role of WSB-1 on metastasis 
promotion was evaluated in vitro and in vivo.  
Results: High WSB1 expression was associated with decreased DMFS in ER- and PR- breast 
cancer patients. Surprisingly, WSB1 expression was not positively correlated with known 
hypoxic gene expression signatures in patient samples. Our study is the first to show that 
WSB-1 knockdown led to decreased metastatic potential in breast cancer hormone receptor-
negative models in vitro and in vivo. WSB-1 knockdown was associated with decreased 
MMP (metalloproteinase) activity, VEGF (vascular endothelial growth factor) secretion, and 
angiogenic potential.  
Conclusions: Our data suggests that WSB-1 may be an important regulator of aggressive 
metastatic disease in hormone receptor-negative breast cancer. WSB-1 could therefore 
represent a novel regulator and therapeutic target for secondary breast cancer in these 
patients. 
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Introduction 
Breast cancer is the second most common cancer type worldwide, affecting one in eight 
women in the UK (Ferlay et al, 2015). Hormone receptor (HR) status is critical in evaluating 
survival rates and determining therapeutic approaches. Triple negative breast cancer (TNBC) 
(no detectable ER (oestrogen receptor), PR (progesterone receptor) or HER2 (human 
epidermal growth factor receptor) expression), is associated with both highest metastatic 
potential and worst overall survival (Prat et al, 2015).   
Metastatic spread is responsible for the majority of cancer-associated deaths, and it has been 
extensively demonstrated that tumour microenvironmental factors, such as hypoxia, are major 
drivers of metastatic disease (Rankin & Giaccia, 2016). Tumour hypoxia arises as a 
consequence of irregular perfusion of the tumour mass, increased metabolic demand from 
rapidly proliferating cells, as well as deregulated and non-productive angiogenesis (Brown & 
Giaccia, 1998). The degree of tumour hypoxia has been shown to be associated with 
decreased patient survival (Vaupel et al, 2004). Hypoxia gene expression signatures have 
demonstrated that breast cancers are hypoxic and particularly ER-negative (ER-), PR-
negative (PR-), and TNBC tumours (Bernardi & Gianni, 2014; Chi et al, 2006). Hypoxia-
inducible factors (HIFs) are transcription factors consisting of alpha (HIF1α and HIF2α) and 
beta (HIF1β/ARNT) subunits, which act as key regulators of hypoxic biology by regulating 
the expression of genes involved in pro-tumourigenic and pro-metastatic pathways (Rankin & 
Giaccia, 2016; Semenza, 2012). Recently, the E3 ligase WSB-1 (WD-40 repeat-containing 
SOCS Box protein) was identified as a transcriptional target of HIF (Cao et al, 2015; Tong et 
al, 2013). WSB-1 is the substrate recognition element of an ECS (Elongin Cullin SOCS box) 
E3 ubiquitin ligase complex (Dentice et al, 2005). It has been proposed that a specific 
isoform of WSB-1 promoted cell proliferation in pancreatic cancer models (Archange et al., 
2008) and that WSB-1 was involved in chemoresistance in hepatocellular cancer cells (Tong 
Poujade et al   Role of WSB-1 in breast cancer 
 
4 
 
et al, 2013). WSB-1 expression was recently associated with increased metastatic potential in 
osteosarcoma and lung adenocarcinoma (Cao et al, 2015; Kim et al, 2015). Therefore, WSB-
1 appears to play an important role in tumour progression and resistance to chemotherapy, 
but these effects appear to be tumour-type specific, and the precise WSB-1 mechanisms of 
action remain elusive.  
 
This study is the first to investigate the role of WSB-1 in breast cancer biology and 
progression, particularly in HR-independent backgrounds. High WSB-1 expression was 
associated with decreased DMFS only for HR-negative cases. Interestingly, although WSB-1 
was induced in hypoxic conditions, it was not associated with a canonical hypoxic response 
in breast cancer. WSB-1 knockdown led to decreased cellular invasion of HR-negative cell 
line models. Importantly, this study is the first to show that WSB-1 knockdown led to 
decreased angiogenic potential, through modulation of MMP expression and activity and 
VEGF secretion. Finally, we showed that knockdown of WSB-1 in this HR-negative model 
led to decreased metastatic seeding and growth in vivo. This study suggests WSB-1 plays a 
significant role in breast cancer, particularly in a HR and hypoxic signalling-independent 
context.  
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Materials and Methods 
 
Cell lines and hypoxia treatment 
MDA-MB-231, MDA-MB-468, MDA-MB-361, MDA-MB-436, BT474, T47D, and MCF-7 
breast cancer cell lines and Human Mammary Epithelial Cells (HMEpC) were purchased 
from ATCC (US) or ECCAC (UK).  Breast cancer lines were grown in DMEM (Corning) 
and HMEpC in HMEC Growth Medium (Lonza, UK), both supplemented with 10% FBS. All 
cell lines were routinely tested as negative for mycoplasma. Cells were maintained at 5% 
CO2 and 37oC. Hypoxia treatments were performed in a H35 Hypoxystation (Don Whitley 
Scientific) with humidified atmosphere containing 2% O2, 5% CO2 at 37oC.  
 
Absolute quantitative PCR  
A standard curve was prepared containing known number of WSB-1 copies, using the 
pFLAG-CMV2 plasmid containing the WSB1 gene (a kind gift from Prof. Hironobu Asao, 
Yamagata University, Japan) as a template (Nara et al, 2011). The standard samples were 
analysed alongside unknown samples using QuantiFAST SYBR Green (Qiagen) in the 
StepOnePlus™ Real-Time PCR System (Thermo Scientific). 
 
Quantitative real-time PCR 
Transcript levels in cell line samples were monitored by QuantiFAST SYBR Green (Qiagen) 
using the StepOnePlus™ Real-Time PCR System (Thermo Scientific). Transcript expression 
levels were normalised to B2M (β-2-Microglobulin). Primer sequences are available in 
Supplementary Information.  
Transcript levels in TissueScan breast microarray plates (panels I, II, IV) (OriGene) were 
analysed using TaqMan qPCR SsoAdvanced Universal Probes for WSB1 (qHsaCIP0050519), 
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CA9 (qHsaCIP0031395) (BioRad), and B2M (4326319E) (Applied Biosystems). Patient 
information is available in Supplementary Information. 
 
Breast cancer patient DMFS analysis 
Kaplan-Meier curves for DMFS were generated using the KM-plotter tool 
(http://kmplot.com/analysis) (Gyorffy et al, 2010). The analysis used microarray data from 
1809 breast cancer patients. Analyses were performed for the following groups: all patients, 
ER+, ER-, PR+, or PR- patients. Analysis of WSB1 expression was performed using the mean 
expression of four WSB1 Affymetrix probes: 201294_s_at, 201295_s_at, 201296_s_at, and 
210561_s_at. Patients were grouped as having high or low WSB1 expression, and median 
expression was used as the cut-off. 
 
Gene expression correlation analysis in cancer datasets 
RNA-sequencing datasets (RNA Seq V2 RSEM) for breast invasive carcinoma tumours were 
downloaded from the TCGA project accessed through cBioportal 
(http://www.cbioportal.org). These datasets included all patients (n=1110), ER+ patients 
(n=593) and ER- patients (n=174). To examine WSB1 expression against hypoxia metagene 
signature (Buffa et al, 2010) or the 26-gene hypoxia signature (Eustace et al, 2013), raw data 
for each sequenced gene and WSB1 were rescaled to set the median equal to 1. Expression 
values for hypoxia signatures was determined by quantifying the median expression of 
signature genes. Log10 conversion of the hypoxia signatures were plotted against Log10 
conversion of rescaled data for WSB1. 
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Cell lysis and Western blotting 
Whole cell lysates (WCL) were prepared using UTB (9 M urea, 75 mM TRIS-HCl pH 7.5 
and 0.15 M β-mercaptoethanol) and immunoblotted as previously (Pires et al, 2010). For 
protein presence in conditioned media, cells were incubated 24 h with serum-free media and 
media was concentrated using Vivaspin 4 ultrafiltration spin column (Sartorius). Antibodies 
used were anti-WSB-1 (Genetex), anti-HIF1α (BD-Biosciences), anti-MMP1 (R&D 
Systems), anti-MMP2 (Cell Signaling Technology), anti-MMP14 (Abcam). Anti-GAPDH 
(BD-Biosciences) was used as loading control. Densitometric analysis of band intensity was 
performed using ImageJ software (NIH).  
 
siRNA knockdown 
For transient knockdown experiments, cells were transfected using DharmaFECT1 (GE 
Dharmacon), as per manufacturer’s instructions. siRNA oligos used were: Non-Targeting 
siRNA and siGENOME SMARTpool WSB-1 siRNA (GE Dharmacon). 
 
VEGF ELISA and in vitro angiogenesis branch forming assay 
Quantification of VEGF in conditioned media was detected using the VEGF ELISA kit 
(Invitrogen), as per manufacturer’s instructions. 
HUVEC (Human Umbilical Vein Endothelial Cells) were grown in complete EGM 
(Endothelial Cell Growth Medium) (Lonza). Branch forming assay was performed using the 
In Vitro Angiogenesis Assay Kit (Merck Millipore), as per manufacturers’ instructions. 
Branching was quantified by scoring the number of branching points in three random fields 
per replicate per experiment (Chan et al, 2009). 
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In vitro cellular invasion assays 
Cellular invasion assays were performed using Matrigel coated or uncoated transwell 
chambers (BD Bioscience) as per manufacturer’s instructions and as previously described 
(Coutts et al, 2011). Cells were then counted in three distinct fields per triplicate well, 
histograms depict average invasion index. 
 
Gelatine zymography 
Conditioned media was processed as described before, and separated through a non-
denaturing 10% acrylamide gel containing 1 mg/mL gelatine. Complete media (DMEM 
supplemented with 10% FBS) was used as a control. Gelatine gel was incubated in renaturing 
buffer (Novex) 1 h and in 1X developing buffer (Novex) at 37°C overnight. Gel was stained 
in Coomassie-blue solution as previously described (Frankowski et al, 2012). 
 
Mammosphere formation assay 
Mammosphere formation assay was performed as previously described (Pires et al, 2014). In 
brief, 2500 cells were seeded in wells coated with Matrigel (BD Biosciences, USA) diluted 
1:1 in serum free media. Mammospheres were grown for 10-14 days and imaged. Diameters 
were determined using ImageJ software (NIH). At least 150 mammospheres were measured 
per condition.  
 
Experimental metastasis models 
MDA-MB-231 cells were stably transfected with WSB-1 shRNA- or non-targeting shRNA-
containing plasmids (OriGene; sequence details in Supplementary Information) using 
TurboFect as per manufacturer’s instructions (Fisher Scientific). 5x105 cells were injected 
into the tail vein of female CD-1 nude mice aged 5-7 weeks (Charles River) (n=6 per group). 
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All animal work was performed in accordance with the Animals (Scientific Procedures) Act 
1986 and the NCRI guidelines for the use of animals in cancer research (Workman et al, 
2010), using protocols approved by the local Animal Welfare and Ethical Review Body 
(AWERB) under Home Office Project License number 60/4549 held by Dr. Cawthorne. 
Haematoxylin and eosin (H&E) staining of equally distanced paraffin embedded lung 
sections was performed as previously reported (Pires et al, 2010). Images were acquired 
using an Eclipse 80i microscope (Nikon), using the Image Pro Premier software (Media 
Cybernetics). Image analysis was performed using Image J software (NIH). 
 
Statistical analysis 
Statistical significance was determined by Student’s t-test (one variable) or 2-way ANOVA 
with Tukey correction (multiple variables). For the tissue cDNA microarray analyses, 
significance was determined by Kruskal-Wallis test for non-parametric data. Gene expression 
correlation and statistical significance were determined by calculating Spearman’s rho rank 
correlation coefficients and two-tailed P. Error bars represent mean ± SEM.  
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Results 
 
High WSB1 expression is associated with decreased DMFS in HR-negative breast 
cancer patients 
In order to evaluate the expression of WSB-1 in breast cancer, we analysed the levels of 
WSB1 transcript in both a panel of cell lines and patient samples (clinical information noted 
in Supplementary Table 1). WSB1 was not shown to be consistently up- or down-regulated 
between normal mammary epithelial cells and breast cancer cells (Figure 1A). WSB1 
expression was also not significantly altered in tumours when compared to normal tissue 
(Figure 1B). Interestingly, when patient cohorts were clustered by subtype or HR status, 
WSB1 expression was significantly lower in the most aggressive tumours, such as HR- and 
TNBC (Figure S1). Analysis of a larger cohort (TCGA dataset, 1100 patients) also indicated 
that WSB1 expression is decreased in breast cancer samples (Figure S2). We then asked 
whether, within breast cancer patient cohorts, differential WSB-1 expression was associated 
with differences in survival. For this, we determined the impact of WSB1 expression on 
several aspects of patient survival, including Overall Survival (OS), Relapse Free Survival 
(RFS), and Distant Metastasis-Free Survival (DMFS) (Figures 1C-G, S3-S4). Importantly, 
although WSB1 expression did not impact DMFS for the whole patient cohort (Figure 1C), 
WSB1 expression levels higher than median were associated with significantly decreased 
DMFS for ER- and PR- patients (Figure 1E, G), but not for ER+ or PR+ patients (Figure 1D, 
F). There was no impact of WSB1 expression on OS, but high WSB1 expression was a poor 
prognostic indicator for RFS for ER- patients (Figures S3-S4). These data demonstrate that, 
although WSB1 expression is not significantly altered between normal and breast tumour 
tissue, higher WSB1 expression levels in HR-negative patients are associated with increased 
likelihood of metastatic disease. 
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WSB1 expression is not associated with hypoxic gene expression signatures in patient 
samples 
WSB-1 has been previously reported to be a hypoxia-inducible factor in a HIF-dependent 
manner in osteosarcoma and hepatocellular carcinoma (Cao et al, 2015; Tong et al, 2013). As 
hypoxic regions are a common feature in breast cancer and known key drivers of metastatic 
potential, we were surprised that WSB-1 expression was not elevated in breast cancers 
compared to normal tissue. However, in breast cancer cell lines, WSB-1 mRNA and protein 
levels were significantly induced in a HIF1-dependent and HIF2-independent manner (Figure 
S5). To investigate HIF1-dependent WSB-1 expression in patient samples, we used the 
TCGA patient cohort dataset to ask whether WSB1 expression was associated with two well-
characterised hypoxia signatures containing well-known HIF targets (Buffa et al, 2010; 
Eustace et al, 2013). Surprisingly, these data showed that WSB1 expression was inversely 
correlated or not correlated with either hypoxia signatures for all cohorts analysed, which 
included both ER+ and ER- patients (Figure 2). This was in contrast with the expression of 
known HIF target genes involved in breast cancer metastasis not included in the hypoxia 
signatures (LOX, LOXL2, LOXL4, CCL2, L1CAM, ANGPT1, and ANGPT2), whose 
expression showed a positive correlation with the signatures (Supplementary Table 2). Taken 
together, these data indicate that WSB-1 can be induced by HIF1 in hypoxic in breast cancer 
cell lines, but that this mechanism is unlikely to be the main driver for WSB-1 expression in 
breast cancers.  
 
WSB-1 affects the expression of pro-tumourigenic and pro-metastatic factors in a HR-
dependent manner  
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It has been previously reported that WSB-1 could itself regulate the stabilisation of HIF1α via 
its E3 ligase, VHL. Here, we also observed an impact of WSB-1 knockdown on HIF1α which 
varied between cell lines (Figure 3A-C, S6). Specifically, WSB-1 knockdown was associated 
with a significant upregulation of HIF1α protein expression in MCF7 cells, but not in MDA-
MB-231 cells. Surprisingly, this was not reflected on the impact of WSB-1 on the expression 
of canonical HIF target genes SLC2A1, VEGFA, CA9, and HK2. WSB-1 knockdown did not 
affect the expression of these genes for HR-positive cell lines MCF7 and T47D, suggesting 
that the increased stabilisation of HIF1 observed (Figure 3A) was not significant to HIF 
activity (Figure 3D-G, S7). Interestingly, in HR-negative cell line MDA-MB-231 cells, 
WSB-1 knockdown led to a significant decrease in VEGFA and HK2 expression in both 
normoxia and hypoxia (Figure 3E, G), with a similar trend observed for MDA-MB-468 HR-
negative cells (Figure S7). Finally, we investigated whether there was any link between the 
expression of WSB1 and HIF targets SLC2A1, VEGFA, CA9, and HK2 in breast cancer 
patients. In contrast to WSB1 expression, which was not different or decreased between 
normal tissue and tumour tissue (Figure 1, S2), the expression of all these genes was 
increased in the tumour tissue (Figure S1). Furthermore, we evaluated the correlation 
between WSB1 expression and SLC2A1, VEGFA, CA9, and HK2 expression in the TCGA 
dataset. Whereas there was a significantly positive correlation between WSB1 and VEGFA 
expression, no significant correlation was observed between the WSB1 and the other genes 
(Figure S8). These data show that WSB-1 can impact the expression of pro-tumourigenic and 
pro-metastatic factors, potentially in a HIF-independent manner.  
 
WSB-1 regulates angiogenic potential in vitro  
As we observed an impact of WSB-1 on the expression of the pro-angiogenic factor VEGFA, 
we further investigated whether VEGF secretion was also affected by WSB-1 knockdown in 
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a HR-dependent manner. WSB-1 knockdown led to a decrease in VEGF secretion in HR-
negative cell lines MDA-MB-231 and MDA-MB-468, but not in HR-positive lines MCF7 
and T47D (Figure 4A). Importantly, this correlated with an effect on angiogenic potential in 
vitro. HUVEC cells incubated with conditioned media from MDA-MB-231 cells transfected 
with WSB-1 siRNA had a significantly decreased endothelial branching ability when 
compared with conditioned media from cells transfected with non-targeting siRNA (Figure 
4B-C). Together, these data implicate WSB-1 in the angiogenic potential of HR-negative 
breast cancer cell lines. 
 
WSB-1 regulates invasiveness of HR-negative cells in vitro 
We then investigated other mechanisms, besides altered angiogenic potential, by which 
WSB-1 could impact the likelihood of metastatic spread in a HR-negative context. WSB-1 
knockdown led to decreased in vitro invasive potential for MDA-MB-231 cells, but not 
MCF7 cells, in hypoxia (Figure 5A). This was not associated with EMT markers expression 
changes (Figure S9). The impact of WSB-1 knockdown on the expression and activity of 
MMPs, key for the metastatic process, was also evaluated. WSB-1 knockdown was 
associated with decreased expression of MMP1 and MMP14 at both transcript and protein 
level, but again only for MDA-MB-231 HR-negative cells (Figures 5B, C). The levels of the 
secreted active form of MMP2, regulated by MMP14, were also decreased by WSB-1 
knockdown, with concomitant decrease in MMP2 gelatinase activity (Figure 5C). These data 
indicate that WSB-1 regulates the expression and activity of key enzymes involved in 
increased invasiveness and extracellular matrix (ECM) remodelling. 
 
WSB-1 promotes metastatic potential in vivo 
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In order to validate our in vitro observation in vivo, we generated WSB-1 shRNA (shWSB-1) 
cell lines and matching non-targeted controls (shNT) in MDA-MB-231 cells (Figure 6, 
S10A). shWSB-1 cells had a lower expression of VEGF both at transcript and protein level 
(Figure 6B-C), similarly to WSB-1 siRNA treated cells (Figure 4). Interestingly, although 
there was no difference in the growth rates or cell cycle profiles of the two cell lines when 
grown in 2D (Figure S10B-C), shWSB-1 cells originated smaller mammospheres in Matrigel 
when compared with shNT cells (Figure 6D).  
MDA-MB-231 shNT or shWSB-1 cells were then injected into the tail veins of two groups of 
mice, and metastatic burden in the lungs was evaluated ex vivo after 12 weeks. Importantly, 
we observed a significantly lower metastatic burden (lesions/lung) for the cohort of animals 
injected with WSB-1 shRNA cells, when compared to the shRNA NT control cells (Figure 
6E-G) in this experimental metastasis model. This was also reflected in the size of metastatic 
lesions present. These observations further validate the pro-metastatic phenotype observed in 
vitro, and indicate that WSB-1 is necessary for the metastatic seeding and growth of HR- 
breast cancer cells in vivo.   
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Discussion  
In this study, we have shown that high expression of WSB-1 in breast cancer is a marker for 
increased metastatic disease in HR-negative breast cancer patients. Downregulation of WSB-
1 expression led to decreased angiogenic and invasive potential of HR-negative breast cancer 
cell lines in vitro and metastatic seeding and growth in vivo (Figure S11).  
The present study indicates that increased WSB-1 expression is associated with an increased 
metastatic propensity in ER- and PR- breast cancer patients. This is in accordance with Cao 
and colleagues, who demonstrated that higher WSB-1 levels in metastatic osteosarcoma 
tumours were associated with decreased DMSF, indicating low WSB-1 expression might 
have a good prognostic value for metastasis-free survival (Cao et al, 2015). Kim and 
colleagues investigated WSB-1 expression levels in several cancer types (lung 
adenocarcinoma, melanoma, prostate cancer and bladder cancer) and found that WSB-1 level 
was elevated in metastatic tissues when compared to primary tumours, and that this effect 
was mediated by a regulation of HIF1 function (Kim et al, 2015). Our study is the first to 
show a link between WSB-1 associated metastatic phenotypes and hormone receptor status, 
in particular linked with angiogenesis promotion. VEGF and other pro-angiogenic factors are 
known key players during the metastatic cascade, through increased vascularisation and 
vasculature permeability (Carmeliet & Jain, 2011). Intravasation and extravasation are reliant 
on ECM-remodelling, as well as increased vascular permeability. MMP levels can indicate 
increased invasiveness of cancer cells and reveal an aggressive tumour (Kessenbrock et al, 
2015). Specifically, MMP1 and MMP14 increased expression in breast cancer has been 
correlated with poor prognosis (Bostrom et al, 2011; Yao et al, 2013). In our study, WSB-1 
knockdown led to a decrease in MMP expression and activity. Interestingly, Kim and 
colleagues found that tumour metastasis with high WSB-1 expression presented increased 
expression of MMP2 and MMP9 levels in patients with lung cancer (Kim et al, 2015). 
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We propose that, for HR-negative breast cancer patients, WSB-1 is a key regulator of several 
molecular pathways central to metastatic seeding and growth of HR-negative breast cancer, 
including remodelling of the ECM by MMPs and increased angiogenic sprouting via MMPs 
and VEGF. However, the mechanism behind the impact of WSB-1 function in this context 
remains unclear.  
WSB-1 has been previously reported to be upregulated at the gene and protein level in 
tumour versus normal tissues for cancer types such as osteosarcoma and lung 
adenocarcinoma (Cao et al, 2015; Kim et al, 2015). However, in our study the trends 
observed indicated a decrease in WSB1 expression in patient samples, and particularly in the 
more aggressive tumour types. These differences could be due to our analysis focusing on 
WSB-1 transcript levels, whereas previous studies investigated WSB-1 protein expression, 
indicating other post-transcriptional regulatory processes may be involved. It could also be 
associated with the nature of the tissue samples analysed that would be comprised of many 
different cell types, which could have masked expression pattern changes. 
WSB-1 was previously identified as a HIF1 target gene in osteosarcoma and hepatocellular 
carcinoma (Cao et al, 2015; Tong et al, 2013). We also observed that WSB-1 was 
upregulated in hypoxic conditions in vitro in a HIF1-dependent manner in breast cancer cell 
lines. However, surprisingly, in patient samples WSB1 expression was inversely correlated 
with that of two well-characterised hypoxia gene expression signatures, the majority of which 
are HIF-targets (Buffa et al, 2010; Eustace et al, 2013). This is even more surprising 
considering other HIF-target genes involved in breast cancer metastasis correlated with the 
hypoxia signatures. These data indicate that the hypoxic microenvironment is not a key 
contributor for differences in WSB1 expression in patient samples. It is plausible that WSB-1 
regulation by HIF has a role in earlier stages of tumour development, which are not reflected 
in the later stage patient samples analysed. These data have implications for the link between 
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WSB-1 expression and hypoxia and HIF, and the usefulness of WSB-1 as a hypoxia 
biomarker.  
It has been previously reported that increased WSB-1 activity was associated with altered 
HIF stabilisation and function (Kim et al, 2015). We observed a similar effect of WSB-1 
knockdown on HIF stabilisation in HR-positive, but not in a HR-negative context. 
Interestingly, this is mirrored to a degree in impact of WSB-1 on the expression of canonical 
HIF targets, such as SLC2A1, VEGFA, CA9, and HK2. In the HR-positive cell line MCF7, 
WSB-1 knockdown did not significantly alter gene expression (with a non-significant trend 
for increased expression for SLC2A1, VEGFA, and HK2), which would mirror an increase in 
HIF levels. In the HR-negative cell line MDA-MB-231, WSB-1 knockdown was associated 
with significantly decreased expression of VEGFA and HK2. Furthermore, WSB1 expression 
in patient samples did not correlate with several HIF targets including HK2, SLC2A1, and 
CA9 in breast cancer patient samples, unlike that shown in other tumour types (Cao et al, 
2015; Kim et al, 2015). This further indicates that the role of WSB-1 in breast cancer HR-
negative cells might not be fully dependent on HIF activity, and that other transcription 
factors are potentially involved. It is also plausible that WSB-1 could regulate the expression 
of only a selected number of HIF target genes, rather that all HIF-dependent expression, as it 
is the case in breast cancer, respectively, for co-factors p300 and DEK for GLUT-1 (SLC2A1) 
and VEGF (VEGFA) expression (Vleugel et al, 2006; Zhang et al, 2016). 
Breast cancer is the second most represented cancer type worldwide and metastatic (or 
secondary) breast cancer is responsible for the majority of patient deaths. Improvement of 
diagnosis and early detection of metastatic propensity, and the identification of relevant 
molecular players continue to be areas of unmet need. We have shown a novel role for WSB-
1 in promotion of metastasis seeding and growth in breast cancer, suggesting that WSB-1 
regulates key pathways for the establishment of secondary breast cancer in HR-negative 
Poujade et al   Role of WSB-1 in breast cancer 
 
18 
 
patients, an area identified as of key importance in the field (Eccles et al, 2013). Further 
clarification of the regulatory pathways downstream of WSB-1 will help to further elucidate 
the biology of these aggressive and invasive breast cancers, and potentially uncover novel 
potential therapeutic targets.  
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Titles and Legends to Figures 
 
Figure 1 - High WSB1 expression is associated with decreased Distant Metastasis-Free 
Survival (DMFS) in HR-negative breast cancer patients 
(A) WSB-1 copy number was measured by absolute qPCR in non-cancer primary breast cell 
line HMEpC and several breast cancer cell lines. n=3 (B) WSB1 transcript levels were 
analysed in tissue cDNA microarrays. Dot plots represent samples arranged as Normal 
(n=16) and Tumour (n=128). (C) Kaplan–Meier (KM) plots represent DMFS according to 
WSB1 expression in the following cohorts: all patients (n=1609), ER+ (n=122), ER- (n=170), 
PR+ (n=122), and PR- (n=95). Patients were grouped as having ‘High’ (grey) or ‘Low’ 
(Black) WSB1 expression, and median expression used as cut-off. HR: Hazard Ratio * 
p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001 
 
Figure 2 – WSB1 expression is not associated with hypoxic gene expression signatures in 
patient samples 
Correlation expression analysis of WSB1 gene vs hypoxia signatures in The Cancer Genome 
Atlas (TCGA) datasets for breast invasive carcinoma. Log10 conversions of WSB1 median 
expression against median expression of two independent hypoxia signatures (Buffa et al, 
2010; Eustace et al, 2013) is shown for all patients (n=1110), ER+ patients (n=593) and ER- 
patients (n=174). Two-tailed P values are shown for Spearman’s rho rank correlation 
coefficients for each analysis (values inset).  
 
Figure 3 – WSB-1 affects the expression of pro-tumourigenic and pro-metastatic factors 
in a HR-dependent manner  
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MCF7 and MDA-MB-231 cells were transfected with WSB-1 (siWSB-1) or non-targeting 
siRNA (siNT). Cells were exposed to 20% or 2% O2. (A-C) WSB-1 and HIF1α protein levels 
were determined by Western blot. Representative blots (n=3) are shown in (A), densitometry 
in (B-C). (D-G) Transcript levels of WSB1 and other HIF-dependent genes were assessed 
after 24h exposure to 20% or 2% O2. Histograms represent average of n=3 experiments.  
* p<0.05; ** p<0.01; **** p<0.0001 
 
Figure 4- WSB-1 regulates angiogenic potential in vitro  
(A) MDA-MB-231, MDA-MB-468, MCF7, and T47D cells were transfected with WSB-1 
(siWSB-1) or non-targeting siRNA (siNT), and exposed 24h to 20% or 2% O2. VEGF levels 
in conditioned media were quantified by ELISA. Histogram represents average of n=3 
experiments. (B) Angiogenic potential was assessed using in vitro branch forming assays 
using conditioned media from MDA-MB-231 cells transfected with siWSB-1 or siNT. 
Histogram represents average of n=3 experiments. (C) Inset microscopy images are 
representative of each condition. Scale bar represents 200 µm. * p<0.05; ** p<0.01; *** 
p<0.001; **** p<0.0001 
 
Figure 5 - WSB-1 regulates invasiveness of HR-negative cells in vitro  
MCF7 and MDA-MB-231 cells were transfected with siWSB-1 or siNT. (A) Cells were 
seeded in control (uncoated) or Matrigel-coated Transwell inserts and allowed to invade for 
18h at 20% or 2% O2. Invasion index = % invasion siWSB-1/% invasion siNT. Histograms 
represent n=4 experiments. (B) Transcript levels of MMP1 and MMP14 were assessed after 
24h exposure to 20% or 2% O2. Histograms represent average of n=3 experiments. (C) 
MDA-MB-231 cells were transfected with either siWSB-1or siNT, and exposed to 20% or 
2% O2 for 24h. Whole cell lysates (WCL) or conditioned media samples were analysed by 
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Western blotting for the expression of HIF1α, MMP14, MMP2, MMP1. Gelatine 
Zymography was used to determine the activity of MMP2 in conditioned media samples. 
Representative blots and zymograms are shown (n=5). * p<0.05; ** p<0.01; **** p<0.0001 
 
Figure 6 – WSB-1 promotes metastatic potential in vivo 
MDA-MB-231 cells were stably transfected with WSB-1 (shRNA WSB-1) or non-targeting 
shRNA (shRNA NT) constructs. The WSB-1 shRNA construct #1 was selected, as it led to 
the most efficient WSB-1 knockdown (Supplementary Figure 10). (A) WSB-1 protein levels 
were assessed by Western blotting. 
(B-C) Histograms represent VEGFA mRNA expression and VEGF secretion as previous 
described, average of n=3 experiments. (D) Mammospheres were established from shNT and 
shWSB-1 MDA-MB-231 cells. Histogram represents the average mammosphere diameter per 
condition per individual experiment. Representative images are shown (n=4).  
(E-G) 5x105 cells were injected into the tail vein of female CD-1 Nude mice (n=6 per group). 
After 15 weeks, mice were sacrificed and lung tissue was collected and fixed. For each 
animal, the right lung was sectioned into 10 µm sections and a total of 10 equally distanced 
sections were H&E stained, imaged (10X objective), and scored for presence of metastatic 
foci. The metastatic lesions were also measured. The total number of metastatic foci per lung 
per group is represented in the scatter plot (E), and the histogram represents the average area 
occupied by metastatic lesions in relation to total lung area (F). Representative example of a 
section of each group is shown in (G). Arrowheads indicate the location of metastatic lesions. 
* p<0.05 
Poujade et al   Role of WSB-1 in breast cancer 
 
23 
 
References 
Archange C, Nowak J, Garcia S, Moutardier V, Calvo EL, Dagorn JC, Iovanna JL (2008) The WSB1 gene is involved 
in pancreatic cancer progression. PloS one 3(6): e2475 
 
Bernardi R, Gianni L (2014) Hallmarks of triple negative breast cancer emerging at last? Cell Res 24(8): 904-5 
 
Bostrom P, Soderstrom M, Vahlberg T, Soderstrom KO, Roberts PJ, Carpen O, Hirsimaki P (2011) MMP-1 
expression has an independent prognostic value in breast cancer. BMC cancer 11: 348 
 
Brown JM, Giaccia AJ (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer 
therapy. Cancer Res 58(7): 1408-16. 
 
Buffa FM, Harris AL, West CM, Miller CJ (2010) Large meta-analysis of multiple cancers reveals a common, 
compact and highly prognostic hypoxia metagene. Br J Cancer 102(2): 428-35 
 
Cao J, Wang Y, Dong R, Lin G, Zhang N, Wang J, Lin N, Gu Y, Ding L, Ying M, He Q, Yang B (2015) Hypoxia-
Induced WSB1 Promotes the Metastatic Potential of Osteosarcoma Cells. Cancer Res 75(22): 4839-51 
 
Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473(7347): 
298-307 
 
Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, Giaccia AJ (2009) Tumor vasculature is regulated by 
PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer cell 15(6): 527-38 
 
Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, Salim A, Wang Y, Kristensen GB, Helland A, Borresen-
Dale AL, Giaccia A, Longaker MT, Hastie T, Yang GP, van de Vijver MJ, Brown PO (2006) Gene expression 
programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 
3(3): e47 
 
Coutts AS, Pires IM, Weston L, Buffa FM, Milani M, Li JL, Harris AL, Hammond EM, La Thangue NB (2011) 
Hypoxia-driven cell motility reflects the interplay between JMY and HIF-1alpha. Oncogene 30(48): 4835-42 
 
Dentice M, Bandyopadhyay A, Gereben B, Callebaut I, Christoffolete MA, Kim BW, Nissim S, Mornon JP, Zavacki 
AM, Zeold A, Capelo LP, Curcio-Morelli C, Ribeiro R, Harney JW, Tabin CJ, Bianco AC (2005) The Hedgehog-
inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the 
developing growth plate. Nature cell biology 7(7): 698-705 
 
Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant 
HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker 
LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM, 
Foster C, Gallagher WM, Garcia-Closas M, Gee JM, Gescher AJ, Goh V, Groves AM, Harvey AJ, Harvie M, 
Hennessy BT, Hiscox S, Holen I, Howell SJ, Howell A, Hubbard G, Hulbert-Williams N, Hunter MS, Jasani B, Jones 
LJ, Key TJ, Kirwan CC, Kong A, Kunkler IH, Langdon SP, Leach MO, Mann DJ, Marshall JF, Martin L, Martin SG, 
Macdougall JE, Miles DW, Miller WR, Morris JR, Moss SM, Mullan P, Natrajan R, O'Connor JP, O'Connor R, 
Palmieri C, Pharoah PD, Rakha EA, Reed E, Robinson SP, Sahai E, Saxton JM, Schmid P, Smalley MJ, Speirs V, 
Stein R, Stingl J, Streuli CH, Tutt AN, Velikova G, Walker RA, Watson CJ, Williams KJ, Young LS, Thompson AM 
Poujade et al   Role of WSB-1 in breast cancer 
 
24 
 
(2013) Critical research gaps and translational priorities for the successful prevention and treatment of breast 
cancer. Breast cancer research : BCR 15(5): R92 
 
Eustace A, Mani N, Span PN, Irlam JJ, Taylor J, Betts GN, Denley H, Miller CJ, Homer JJ, Rojas AM, Hoskin PJ, 
Buffa FM, Harris AL, Kaanders JH, West CM (2013) A 26-gene hypoxia signature predicts benefit from hypoxia-
modifying therapy in laryngeal cancer but not bladder cancer. Clinical cancer research : an official journal of 
the American Association for Cancer Research 19(17): 4879-88 
 
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer 
incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 
136(5): E359-86 
 
Frankowski H, Gu YH, Heo JH, Milner R, Del Zoppo GJ (2012) Use of gel zymography to examine matrix 
metalloproteinase (gelatinase) expression in brain tissue or in primary glial cultures. Methods Mol Biol 814: 
221-33 
 
Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z (2010) An online survival analysis tool to 
rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. 
Breast cancer research and treatment 123(3): 725-31 
 
Kessenbrock K, Wang CY, Werb Z (2015) Matrix metalloproteinases in stem cell regulation and cancer. Matrix 
biology : journal of the International Society for Matrix Biology 44-46: 184-90 
 
Kim JJ, Lee SB, Jang J, Yi SY, Kim SH, Han SA, Lee JM, Tong SY, Vincelette ND, Gao B, Yin P, Evans D, Choi DW, 
Qin B, Liu T, Zhang H, Deng M, Jen J, Zhang J, Wang L, Lou Z (2015) WSB1 promotes tumor metastasis by 
inducing pVHL degradation. Genes Dev 29(21): 2244-57 
 
Nara H, Onoda T, Rahman M, Araki A, Juliana FM, Tanaka N, Asao H (2011) WSB-1, a novel IL-21 receptor 
binding molecule, enhances the maturation of IL-21 receptor. Cell Immunol 269(1): 54-9 
 
Pires IM, Bencokova Z, Milani M, Folkes LK, Li JL, Stratford MR, Harris AL, Hammond EM (2010) Effects of Acute 
versus Chronic Hypoxia on DNA Damage Responses and Genomic Instability. Cancer Res 70(3): 925-35 
 
Pires IM, Blokland NJ, Broos AW, Poujade FA, Senra JM, Eccles SA, Span PN, Harvey AJ, Hammond EM (2014) 
HIF-1alpha-independent hypoxia-induced rapid PTK6 stabilization is associated with increased motility and 
invasion. Cancer Biol Ther 15(10): 1350-7 
 
Prat A, Pineda E, Adamo B, Galvan P, Fernandez A, Gaba L, Diez M, Viladot M, Arance A, Munoz M (2015) 
Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 24 Suppl 2: S26-35 
 
Rankin EB, Giaccia AJ (2016) Hypoxic control of metastasis. Science 352(6282): 175-80 
 
Semenza GL (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. 
Trends Pharmacol Sci 33(4): 207-14 
 
Poujade et al   Role of WSB-1 in breast cancer 
 
25 
 
Tong Y, Li QG, Xing TY, Zhang M, Zhang JJ, Xia Q (2013) HIF1 regulates WSB-1 expression to promote hypoxia-
induced chemoresistance in hepatocellular carcinoma cells. FEBS Lett 587(16): 2530-5 
 
Vaupel P, Mayer A, Hockel M (2004) Tumor hypoxia and malignant progression. Methods Enzymol 381: 335-54 
 
Vleugel MM, Shvarts D, van der Wall E, van Diest PJ (2006) p300 and p53 levels determine activation of HIF-1 
downstream targets in invasive breast cancer. Hum Pathol 37(8): 1085-92 
 
Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, 
Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA (2010) Guidelines 
for the welfare and use of animals in cancer research. British journal of cancer 102(11): 1555-77 
 
Yao G, He P, Chen L, Hu X, Gu F, Ye C (2013) MT1-MMP in breast cancer: induction of VEGF-C correlates with 
metastasis and poor prognosis. Cancer cell international 13(1): 98 
 
Zhang Y, Liu J, Wang S, Luo X, Li Y, Lv Z, Zhu J, Lin J, Ding L, Ye Q (2016) The DEK oncogene activates VEGF 
expression and promotes tumor angiogenesis and growth in HIF-1alpha-dependent and -independent 
manners. Oncotarget 7(17): 23740-56 
 
 
 






